Here’s my new story for Quartz on cyborg and #transhumanist bill of rights! It offers a look at the various ideas around the world surrounding this provocative issue:
Transhumanists are pushing the boundaries of what it means to be human. Our governing principles may need to progress along with them.
Okay, Science time.
This is an unedited manuscript that has been accepted for publication. Nature Research are providing this early version of the manuscript as a service to our customers. The manuscript will undergo copyediting, typesetting and a proof review before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.
We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.
John Lewis of Oisin Biotechnologies discussed senolytics, which are drugs that kill senescent cells. He explained the differences between healthy and senescent cells along with the senescence-associated secretory phenotype (SASP) responsible for systemic inflammation. He went into detail about senolytics and what his company looks for when creating them, including details about suicide genes and biomarkers of senescence. He also discussed issues with bringing these drugs to humans and suggested oncology as a possible method for bringing them to the clinic.
WASHINGTON — Blue Origin is joining forces with three other major aerospace firms in a “national team” to develop a human lunar lander for NASA.
The company’s founder, Jeff Bezos, announced Oct. 22 his intent to work with Lockheed Martin, Northrop Grumman and Draper on the unnamed lunar lander, the proposal for which they will submit to NASA for its Human Landing Services competition.
“I am excited to announce that we have put together a national team to go back to the moon,” he said during an onstage interview at the 70th International Astronautical Congress here, where he received an Excellence in Industry award. “We could not ask for better partners.”
Jeff Bezos’ aerospace company, Blue Origin, no longer plans to build its giant lunar lander for NASA by itself. The company announced today that it is teaming up with three other legacy space companies — Lockheed Martin, Northrop Grumman, and Draper — to develop a lunar landing system for the space agency that is fully capable of taking humans to and from the Moon’s surface.
The air taxi’s maker, German aviation start-up Volocopter, has previously conducted public demonstration flights in Germany, Dubai and Finland.
“[This] is an important milestone for the introduction of urban air mobility, simply because we give people the image in their mind and the opportunity to see how the vehicle behaves in the air, and how quiet it is in full flight,” Volocopter CEO Florian Reuter told Al Jazeera after the test run.
Volocopter is one of several companies developing a drone equivalent to traditional helicopters, and proponents say electrically powered air taxis offer a safer, quieter, emissions-free alternative.
A ‘GOD-LIKE’ alien civilisation has been discovered deep in the cosmos, according to an extraterrestrial hunter.
Banner Image: The 2019 ozone hole reached its peak extent of 6.3 million square miles (16. 4 million square kilometers) on Sept. 8. Abnormal weather patterns in the upper atmosphere over Antarctica dramatically limited ozone depletion this year. Credit: NASA
By: Ellen Gray NASA’s Earth Science News Team
By: Theo Stein
Marine geophysicist discovered a depression, likely a volcanic caldera twice the size of Yellowstone, hidden in the Philippine Sea.
Just in time for Halloween, doctors in France say they witnessed a real-life horror tale involving an antibiotic-resistant superbug. In less than a month, their patient’s infection evolved resistance to the last-resort drug they had used to treat it. Thankfully, the doctors were still able to defeat the microscopic threat—and the case may have uncovered a peculiar weakness in the germ.
According to the report, published in the journal Antimicrobial Agents and Chemotherapy, a young child had been dealing with recurrent infections of the bacteria Pseudomonas aeruginosa for over two years. P. aeruginosa is an opportunistic infection that sickens tens of thousands of already weakened people in hospitals and other health-care settings in the U.S. a year. In these people, it can cause serious infections.
